Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 30K
5: R1 Cover HTML 47K
8: XML IDEA XML File -- Filing Summary XML 11K
6: XML XBRL Instance -- clbs-20220929_htm XML 21K
7: EXCEL IDEA Workbook of Financial Reports XLSX 8K
3: EX-101.LAB XBRL Labels -- clbs-20220929_lab XML 73K
4: EX-101.PRE XBRL Presentations -- clbs-20220929_pre XML 35K
2: EX-101.SCH XBRL Schema -- clbs-20220929 XSD 10K
9: JSON XBRL Instance as JSON Data -- MetaLinks 12± 17K
10: ZIP XBRL Zipped Folder -- 0000320017-22-000094-xbrl Zip 15K
Registrant's telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
i☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon
Stock, par value $0.001 per share
iLSTA
The iNasdaq Capital Market
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
i☐ Emerging growth company
o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01Other Events.
As previously disclosed, on February 18, 2022, Lisata Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that, for the preceding 30 consecutive trading days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rules, the Company was provided an initial period of 180 calendar days, ending August 17, 2022, to regain compliance with the Bid Price Requirement, and it was subsequently provided with a second period of 180 calendar days, ending February 13, 2023, to regain compliance with the
Bid Price Requirement.
On September 29, 2022, the Company received a letter from the Staff notifying the Company that since the closing bid price of the Common Stock for the previous 10 consecutive business days, from September 15, 2022 through September 28, 2022, had been at $1.00 per share or greater, the Company had regained compliance with the Bid Price Requirement, and that this matter is now closed.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
